Acadia Pharmaceuticals Inc. (ACAD)

[H2R]

Brent Jensen (SA) believes "approval is highly likely"
March 23, part of the following article:

http://seekingalpha.com/article/3960453-biotech-forum-daily-digest-valeants-ceo-steps-sarepta-become-battleground-stock-spotlight

ACADIA Pharmaceuticals (NASDAQ:ACAD) continues to be the subject of positive analyst commentary in front of an upcoming approval decision from the FDA around its primary drug candidate. A five-star rated analyst (TipRanks) at JMP Securities reiterated his Buy rating and $43 price target on ACAD. Earlier this month, Leerink Swann reiterated their $40 price target on the stock, on which it has a Buy rating. ACAD currently sells for approximately $21.50.

Next Tuesday an advisory committee which will consist of a panel of doctors will review ACADIA's clinical data in Parkinson's disease psychosis for its compound NUPLAZID. Both analysts and I think this AdComm committee will recommend approval and ACADIA has a PDUFA date of May 1st with the FDA. Although this is high risk/high reward play on NUPLAZID being approved, I believe approval is highly likely and have a small, speculative stake in this biotech. NUPLAZID is also in trials for treatments for other indications.